Compare BCML & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCML | AVIR |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.4M | 266.4M |
| IPO Year | N/A | 2020 |
| Metric | BCML | AVIR |
|---|---|---|
| Price | $28.19 | $3.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $32.00 | $6.00 |
| AVG Volume (30 Days) | 25.2K | ★ 393.0K |
| Earning Date | 01-22-2026 | 11-12-2025 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $94,896,000.00 | N/A |
| Revenue This Year | $0.51 | N/A |
| Revenue Next Year | $10.33 | N/A |
| P/E Ratio | $13.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.22 | $2.46 |
| 52 Week High | $33.15 | $4.02 |
| Indicator | BCML | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 36.86 | 58.89 |
| Support Level | $27.59 | $3.29 |
| Resistance Level | $30.20 | $3.63 |
| Average True Range (ATR) | 0.89 | 0.14 |
| MACD | -0.44 | 0.00 |
| Stochastic Oscillator | 9.17 | 63.41 |
BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).